Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

作者：Kelly Allott, Walid Yassin, Luis Alameda, Tashrif Billah, Owen Borders, Kate Buccilli, Ricardo E. Carrión, Rolando I Castillo-Passi, Kang Ik K. Cho, Kota Chin, Michael J. Coleman, Beau‐Luke Colton, Sebastián Corral, Dominic Dwyer, Kristina Ballestad Gundersen, Ruben C. Gur, Gil D. Hoftman, Grace R. Jacobs, Sinéad Kelly, Kathryn E. Lewandowski, Patricia Marcy, Priya Matneja, Danielle McLaughlin, Ángela Núñez, Setari Parsa, Nora Penzel, Susan Ray, Jenna Reinen, Kosha Ruparel, Michael Sand, G Santorelli, Johanna Seitz‐Holland, Jessica Spark, Zailyn Tamayo, Andrew Thompson, Sophie Tod, Cassandra Wannan, Alana Wickham, Stephen J. Wood, Eirini Zoupou, Jean Addington, Alan Anticevic, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Lauren M. Ellman, Paolo Fusar‐Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Sung‐Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Covadonga M. Díaz‐Caneja, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Diana O. Perkins, Jesús Pérez, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai Shah, Steven M. Silverstein, Stefan Smesny, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Ofer Pasternak, Sylvain Bouix, Patrick D. McGorry, John M. Kane, René S. Kahn, Carrie E. Bearden, Martha E. Shenton, Scott W. Woods, Barnaby Nelson, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), William S. Stone · 发表于：Schizophrenia · 年份：2025 · DOI：10.1038/s41537-025-00578-1 · 被引用次数：8 · 研究领域：Schizophrenia research and treatment、Functional Brain Connectivity Studies、Mental Health Research Topics

Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.